Herbert Rogers, MD
Internal Medicine · Laurel, MSNPI 1720092331
Payments from drug & device makers
Across 176 payments — averaging $14.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$605
- Merck$354
- Boehringer Ingelheim$227
- Astellas Pharma US Inc$202
- Abbott$166
- AstraZeneca$140
- plus $903 from 26 others
What the payments were for
- Food & beverage$2,597100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 46 | $605 |
| Merck | 22 | $354 |
| Boehringer Ingelheim | 15 | $227 |
| Astellas Pharma US Inc | 13 | $202 |
| Abbott | 11 | $166 |
| AstraZeneca | 10 | $140 |
| E.r. Squibb & Sons, L.L.C. | 10 | $131 |
| Johnson & Johnson | 7 | $108 |
| Sumitomo Pharma America, Inc. | 5 | $87 |
| Novartis | 6 | $84 |
| Amgen | 5 | $73 |
| Global Blood Therapeutics, Inc. | 3 | $45 |
| Inspire Medical Systems, Inc. | 1 | $35 |
| Alkermes, Inc. | 2 | $32 |
| Biogen | 2 | $31 |
| Sanofi-aventis U.S. LLC | 2 | $27 |
| Inari Medical, Inc. | 1 | $22 |
| Dexcom, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
| Exact Sciences | 1 | $19 |
| AbbVie | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Medtronic | 1 | $15 |
| Insulet Corporation | 1 | $14 |
| Redhill Biopharma Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $14 |
| Tandem Diabetes Care, Inc. | 1 | $13 |
| Nabriva Therapeutics, PLC | 1 | $13 |
| GSK | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Lilly USA, LLC | 1 | $12 |
How this compares
$2,597 in reported general payments places this provider in the 75th percentile of 846 internal medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 369 | $172,580 |
| OzempicSemaglutide | 133 | $146,055 |
| JardianceEmpagliflozin | 190 | $108,394 |
| MounjaroTirzepatide | 68 | $78,833 |
| TrulicityDulaglutide | 51 | $60,089 |
| LinzessLinaclotide | 87 | $53,744 |
| XareltoRivaroxaban | 111 | $48,734 |
| FarxigaDapagliflozin Propanediol | 56 | $43,113 |
| JanuviaSitagliptin Phosphate | 62 | $41,142 |
| MyrbetriqMirabegron | 82 | $39,994 |
| CreonLipase/Protease/Amylase | 38 | $38,907 |
| RybelsusSemaglutide | 24 | $37,679 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $34,298 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 50 | $25,273 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $18,227 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $605 | $183,734157 claims |
| Lilly USA, LLCMounjaro, Trulicity | $12 | $138,923119 claims |
| Boehringer IngelheimJardiance | $227 | $108,394190 claims |
| AbbVieLinzess, Creon | $16 | $92,651125 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $140 | $61,34080 claims |
| Johnson & JohnsonXarelto | $108 | $48,734111 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $13 | $47,03288 claims |
| MerckJanuvia | $354 | $41,14262 claims |
| Astellas Pharma US IncMyrbetriq | $202 | $39,99482 claims |
| Redhill Biopharma Inc.Movantik | $14 | $8,32713 claims |
| Sanofi-aventis U.S. LLCLantus | $27 | $4,23355 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 846 internal medicine providers in Mississippi.
Other internal medicine in Laurel
- James HallBrookhaven$4.8M
- Bob HutchinsJackson$4.6M
- Sidney GortonBelzoni$571K
- David PendleyGulfport$336K
- Sarah KerutJackson$319K
- Gabriel HernandezJackson$196K
- Kelly WilkinsonJackson$183K
- Magdy Gorgi-MikhailBiloxi$157K
- Christina BarlowJackson$129K
- Arnold JacksonHattiesburg$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.